ClinicalTrials.gg
RecruitingNCT07213128IN-SPIREDUpdated May 28, 2026

Effect of IMT in Patients After Acute Exacerbations of COPD

An interventional study of Training in Chronic Obstructive Pulmonary Diseases, COPD and Symptom Exacerbation, sponsored by KU Leuven. Recruiting at 12 sites in Belgium. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by KU Leuven · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
358
Allocation
Randomized
Ages
35 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Pulmonary Disease, Chronic Obstructive by KU Leuven — 2 open to participants now, 2 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · KU Leuven.

Planned enrollment
2nd of 19
358 · median 70
Started
2026
the only one that year
No phase
16 of 27
2 open now
Registered
27th of 27
by date

Among the 27 studies in Pulmonary Disease, Chronic Obstructive by KU Leuven, this one is the 2nd largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2026, is one of 16 with no phase, and was the 27th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 27 studies in Pulmonary Disease, Chronic Obstructive by KU Leuven are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 35 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Pulmonary Disease, Chronic Obstructive by KU Leuven, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test whether home-based inspiratory muscle training can reduce hospital readmissions and death in patients recovering from a severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD).

The main questions this study aims to answer are:

Does adding home-based inspiratory muscle training to usual care lower the risk of all-cause hospital readmission or death within 180 days after discharge? Does inspiratory muscle training improve respiratory muscle strength, symptoms of dyspnea, quality of life, and functional capacity compared to usual care?

Researchers will compare patients randomized to:

Intervention group: Home-based inspiratory muscle training plus usual care Control group: Usual care only

to see if inspiratory muscle training leads to fewer readmissions and deaths, and better patient-reported and physiological outcomes.

Participants will:

Be hospitalized for ≥3 days due to AECOPD, age ≥35 years, able to consent, and own a compatible smartphone.

In the intervention group, receives usual care and additionally inspiratory muscle training:

Inspiratory muscle training twice daily for 90 days, then once daily up to day 180, with remote telemonitoring via a smartphone app and online supervised sessions.

The control group will continue with usual care (pharmacological treatment, smoking cessation advice, vaccinations, and referral to pulmonary rehabilitation if available).

Follow-up assessments will include hospital readmissions, survival, and quality of life questionnaires up to 12 months after discharge.

03

Conditions studied

  • Chronic Obstructive Pulmonary Diseases
  • COPD
  • Symptom Exacerbation

Keywords

  • Inspiratory muscle training
  • Respiratory muscle training
  • acute exacerbation
  • chronic obstructive pulmonary disease
04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients admitted to the hospital ≥3 days for AECOPD
  • Read and speak French, Dutch or English
  • Age ≥ 35 years
  • Able to provide
  • Possessing a smartphone, compatible with the tele-monitoring app and able to perform video meetings.

Exclusion criteria

Exclusion Criteria:

  • Patients already performing IMT at time of inclusion
  • Patients with estimated \<90 days
  • Non- pulmonary disease as primary diagnosis
  • Active
  • Inability to perform IMT or response to questionnaires (e.g., neurological/cognitive impairment)
  • Acute instable cardiac arrythmia or ischemia
  • Acute pneumothorax
  • Planned lung volume reduction procedure \<180days
  • Waitlisted for lung transplantation
  • Patients admitted to an in-hospital rehabilitation ward
  • Patients included in other interventional trial related to COPD that would interfere with our trial outcomes.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
358 participants (estimated)

Study arms

  • Experimental
    Intervention

    Other: Training

  • No intervention
    Control

    Patients will receive usual care, including optimal pharmacological therapy per international guidelines, advise on smoking cessation, vaccination, and physical activity participation and advised to attend physiotherapy or a respiratory rehabilitation program based on accessibility and patient preference.

Interventions

  • OtherTraining

    home-based inspiratory muscle training (IMT) will be delivered using a portable IMT device connected via Bluetooth to a smartphone application that provides real-time feedback, adherence monitoring, and telemonitoring by the study team. Patients will train for 365 days following hospital discharge due to an acute exacerbation of COPD: * Intensive phase (Day 0-90): 2 daily sessions, each consisting of 30 breaths against an inspiratory load set by thetelemonitor, with regular online supervised IMT sessions, 7 sessions in total * Maintenance phase (Day 91-180): One daily session of 30 breaths, with sporadic online supervised IMT sessions, 2 sessions in total. * Follow-up phase (Day 181-365): Participants may continue IMT unsupervised. Supervision includes both in-person sessions at hospital visits and online sessions with telemonitors.

06

What researchers measure

Primary outcomes

  1. Composite outcome (all-cause hospital readmission or mortality)

    Time frame: within 180 days after hospital discharge

Secondary outcomes

  1. Composite outcome (all-cause hospital readmission or mortality)

    Occurrence

    Time frame: within 90 days after hospital discharge

  2. Time-to-composite outcome (all-cause hospital readmission or mortality)

    Time-to-event

    Time frame: within 180 days after hospital discharge

  3. Hospital re-admission

    1. Occurrence 2. Reason

    Time frame: Day 28, 90 and 180 after hospital discharge

  4. All-cause mortality

    1. Occurrence 2. Reason

    Time frame: Day 28, 90 and 180 after hospital discharge

  5. Primary care and specialty consultationsc

    Number of days post-discharge

    Time frame: Day 90 and 180 after hospital discharge

  6. Re-exacerbation

    1. Occurrence 2. Number of occurrences/patient post-discharge

    Time frame: Day 90 and 180 after hospital discharge

  7. Change in Forced Expiratory Volume in 1 Second (FEV₁), liters

    \- Mean change in FEV₁ (liters) from baseline, measured by spirometry, according to ATS/ERS guidelines.

    Time frame: Day 90 and 180 after hospital discharge

  8. Change in Forced Expiratory Volume in 1 Second (FEV₁), %pred

    \- Mean change in FEV₁ (% predicted) from baseline, measured by spirometry.

    Time frame: Day 90 and 180 after hospital discharge

  9. Change in Forced Vital Capacity (FVC), liters

    \- Mean change in FVC (liters) from baseline, measured by spirometry.

    Time frame: Day 90 and Day 180 after hospital discharge

  10. Change in Forced Vital Capacity (FVC), %predicted

    \- Mean change in FVC (% predicted) from baseline, measured by spirometry.

    Time frame: Day 90 and Day 180 after hospital discharge

  11. Change in FEV₁/FVC Ratio (%)

    Mean change in the ratio of FEV₁ to FVC (percentage) from baseline, measured by spirometry.

    Time frame: Day 90 and Day 180 after hospital discharge

  12. Change in Functional Residual Capacity (FRC), liters

    \- Mean change in FRC (liters) from baseline, measured by body plethysmography.

    Time frame: Day 180 after hospital discharge

  13. Change in Functional Residual Capacity (FRC), %predicted

    \- Mean change in FRC (% predicted) from baseline, measured by body plethysmography.

    Time frame: Day 180 after hospital discharge

  14. Change in Residual Volume (RV), liters

    \- Mean change in RV (liters) from baseline, measured by body plethysmography.

    Time frame: Day 180 after hospital discharge

  15. Change in Residual Volume (RV), % predicted

    \- Mean change in RV (% predicted) from baseline, measured by body plethysmography.

    Time frame: Day 180 after hospital discharge

  16. Change in Total Lung Capacity (TLC), liters

    \- Mean change in TLC (liters) from baseline, measured by body plethysmography.

    Time frame: Day 180 after hospital discharge

  17. Change in Total Lung Capacity (TLC), %predicted

    \- Mean change in TLC (% predicted) from baseline, measured by body plethysmography.

    Time frame: Day 180 after hospital discharge

  18. Maximal inspiratory pressure (PImax)

    Change from baseline

    Time frame: Day 90 and 180 after hospital discharge

  19. Baseline/Transition Dyspnea Index (BDI/TDI)

    Change from baseline

    Time frame: Day 28, 90, 180 after hospital discharge

  20. EQ-5D-5L questionnaire

    Change from baseline

    Time frame: Day 28, 90, 180 after hospital discharge

  21. COPD Assessment test (CAT)

    Change from baseline

    Time frame: Day 28, 90, 180 after hospital discharge

  22. Adverse events

    1. Occurrence 2. Number of occurrences/patient post-discharge

    Time frame: Day 90, 180 after hospital discharge

  23. Serious adverse events

    1. Occurrence 2. Number of occurrences/patient post-discharge

    Time frame: Day 90 and 180 after hospital discharge

Other outcomes

  1. Intensive care unit admission

    Number of days post-discharge

    Time frame: Day 90, 180, 365 after hospital discharge

  2. Lung function: Diffusion capacity

    Mean of 2 acceptable assessments

    Time frame: Day 180 after hospital discharge

  3. 1 minute sit-to-stand test, Repetitions from Baseline

    Mean change in the number of repetitions completed in the 1-minute sit-to-stand test compared with baseline.

    Time frame: Day 180 after hospital discharge

  4. Number of Participants Achieving the Minimal Important Difference (MID) in the 1-Minute Sit-to-Stand Test

    Number of participants who improved their 1-minute sit-to-stand repetitions by more than the minimal important difference (MID)

    Time frame: Day 180 after hospital discharge

  5. Hospital Anxiety & Depression Scale (HADS)

    Change from baseline

    Time frame: Day 90 and 180 after hospital discharge

  6. EQ-5D-5L

    Change from baseline

    Time frame: Day 365 after hospital discharge

  7. COPD Assessment test (CAT)

    Change from baseline

    Time frame: Day 365 after hospital discharge

  8. Baseline/Transition Dyspnea Index (BDI/TDI)

    Change from baseline

    Time frame: Day 365 after hospital discharge

  9. Hospital re-admission

    Time to event

    Time frame: Day 365 after hospital discharge

  10. All-cause mortality

    1. Time to event 2. Reason

    Time frame: Day 365 after hospital discharge

  11. Rate of AECOPD treated with systemic corticosteroids

    1. Occurrence 2. Time to event

    Time frame: Day 90, 180, 365 after hospital discharge

  12. Rate of AECOPD treated with antibiotics

    1. Occurrence 2. Time to event

    Time frame: Day 90, 180, 365 after hospital discharge

07

Study locations

11 of 12 sites recruiting
  • AZORG
    Aalst, 9300, Belgium
    Recruiting
    • Dimitri Stylemans · Contactdimitri.stylemans@azorg.be · 0032 53 72 42 89
    • Dimitri Stylemans · Principal investigator
    • Piet Vercauter · Sub investigator
  • Campus Joseph Bracops, Hôpitaux Iris Sud
    Anderlecht, 1070, Belgium
    Recruiting
    • Emmanuelle Papleux · Contactepapleux@his-izz.be · 0032 2 432 81 71
    • Olivier Bauwens · Sub investigator
    • Alain Bauler · Sub investigator
    • Emmanuelle Papleux · Principal investigator
  • Centre Hospitalier Universitaire Saint-Pierre
    Brussels, 1000, Belgium
    Recruiting
    • Maria Gabrovska · Contactmaria.gabrovska@stpierre-bru.be · 0032 2 535 42 03
    • Maria Gabrovska · Principal investigator
    • Marie Bruyneel · Sub investigator
    • Sybille Doyen · Sub investigator
    • Sarah Carlier · Sub investigator
  • Grand Hopial de Charleroi
    Charleroi, 6000, Belgium
    Recruiting
    • Antoine Fremault · ContactAntoine.FREMAULT@ghdc.be · 003260 11 12 13
    • Antoine Fremault · Principal investigator
    • Emeline Brenard · Sub investigator
  • Universitair Ziekenhuis Antwerpen
    Edegem, 2650, Belgium
    Not yet recruiting
    • Jo Raskin · ContactJo.Raskin@uza.be · 0032 3 821 32 50
    • Jo Raskin · Principal investigator
    • Therese Lapperre · Sub investigator
  • AZ Maria Middelares
    Ghent, 9000, Belgium
    Recruiting
    • Sarah Loof · ContactSarah.Loof@mijnziekenhuis.be · 00329 246 84 00
    • Sarah Loof · Principal investigator
    • Sofie Van Den Broecke · Sub investigator
  • Universitair Ziekenhuis Gent
    Ghent, 9000, Belgium
    Recruiting
    • Eric Derom · ContactEric.Derom@uzgent.be · 0032 9 332 26 72
    • Eric Derom · Principal investigator
    • Bihiyga Salhi · Sub investigator
    • Thor Hautekiet · Sub investigator
    • Nina Cardinaels · Sub investigator
    • Bénédicte Demeyere · Sub investigator
    • Heleen Demeyer · Sub investigator
  • AZ Groeninge
    Kortrijk, 8500, Belgium
    Recruiting
  • University Hospitals Leuven
    Leuven, 3000, Belgium
    Recruiting
    • Daniel Langer, PhD · Contactdaniel.langer@kuleuven.be · 0032 16 37 64 97
    • Stephanie Everaerts, PhD · Contactstephanie.everaerts@uzleuven.be
    • Marine Van Hollebeke, PhD · Sub investigator
    • Daniel Langer, PhD · Principal investigator
    • Stephanie Everaerts, PhD · Sub investigator
    • Thierry Troosters, PhD · Sub investigator
    • Wim Janssens, PhD · Sub investigator
  • Centre hospitalier universitaire de Liège
    Liège, 4000, Belgium
    Recruiting
    • Vincent Heinen · ContactV.Heinen@chuliege.be · 0032 2 609 54 95
    • Olivier Bonhomme · Sub investigator
    • Vincent Heinen · Principal investigator
  • AZ Delta
    Roeselare, 8800, Belgium
    Recruiting
    • Bernard Bouckaert · Contactbernard.bouckaert@azdelta.be · 003251 69 85 94
    • Bernard Bouckaert · Principal investigator
    • Ulrike Himpe · Sub investigator
    • Ingel Demedts · Sub investigator
    • Hannelore Bode · Sub investigator
  • Centre Hospitalier Universitaire UCL Namur
    Yvoir, 5530, Belgium
    Recruiting
    • Eric Marchand · Contacteric.marchand@chuuclnamur.uclouvain.be · 0032 81 423361
    • Charlotte SCHLESSER · Sub investigator
    • Eric Marchand · Principal investigator
    • Hélène Debatty · Sub investigator
    • Manon Collard · Sub investigator
    • Zoé Detrembleur · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — At this time, there are no plans to share individual participant data (IPD). De-identified participant-level data will not be made publicly available. However, summary results of the trial will be published in peer-reviewed journals and presented at scientific meetings. Researchers interested in secondary analyses may contact the sponsor (UZ Leuven) to discuss possibilities for collaborative projects, subject to approval by the Trial Steering Committee and compliance with applicable regulations and GDPR.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jun 2028, 29 months after the start.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 29 months is above that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2025
First posted
Oct 8, 2025
StartActual
Jan 6, 2026
Primary completionEst.
Jun 2028
CompletionEst.
Feb 2029
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07213128
Lead sponsor
KU Leuven
Collaborators
Hopitaux Iris Sud, Centre Hospitalier Universitaire Saint Pierre, Onze Lieve Vrouw Hospital, AZ Delta, University Hospital, Antwerp, Algemeen Ziekenhuis Maria Middelares, Grand Hôpital de Charleroi, Centre Hospitalier Universitaire UCLouvain Namur, Centre Hospitalier Universitaire de Liege, General Hospital Groeninge, University Hospital, Ghent
Responsible party
Daniel Langer (associate professor Faculty of Movement and Rehabilitation Sciences, KU Leuven) — Principal investigator
First posted
Oct 8, 2025
Start date
Jan 6, 2026
Primary completion
Jun 2028 (estimated)
Completion
Feb 2029 (estimated)
Last update
May 28, 2026

Study contacts

Marine Van Hollebeke, PhD
Contact
marine.vanhollebeke@kuleuven.be
0032498606820
Daniel Langer, PhD
Contact
daniel.langer@kuleuven.be
0032 16 37 64 97
Daniel Langer, PhD
principal investigator · KU Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion